Can a Dual-Pronged antibody outsmart advanced solid tumors?
NCT ID NCT07763639
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the drug's safety, determine the right dose, and get an early look at whether it can help fight the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SI-B036, an experimental bispecific antibody given by intravenous infusion
- What this could lead to
- If successful, this could lead to a new treatment option for advanced head and neck and other solid tumors, potentially slowing or shrinking tumors.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not be effective or may cause significant side effects. The results will need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can engineered immune cells target a common ovarian cancer protein?
- Can a new imaging tracer outperform standard scans in finding hidden tumors?
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Lab-Made immune protein takes on advanced cancers in first human test
- Blood test may let cancer patients take safe breaks from immunotherapy